Ebola virus (EBOV) causes severe and often fatal hemorrhagic fever in humans and
nonhuman primates (NHPs). Currently, there are no licensed vaccines or therapeutics for …

The recombinant vesicular stomatitis virus (rVSV) vector-based monovalent vaccine platform
expressing a filovirus glycoprotein has been demonstrated to provide protection from lethal …

Abstract For Ebola virus (EBOV), 4 different species are known: Zaire, Sudan, Cô te d'Ivoire,
and Reston ebolavirus. The newly discovered Bundibugyo ebolavirus has been proposed …

The recent Ebola virus (EBOV) epidemic in West Africa demonstrates the potential for a
significant public health burden caused by filoviral infections. No vaccine or antiviral is …

Ebola virus (EBOV) is a significant human pathogen that presents a public health concern as
an emerging/re-emerging virus and as a potential biological weapon. Substantial progress …

Background. Outbreaks of filoviral hemorrhagic fever occur sporadically and unpredictably
across wide regions in central Africa and overlap with the occurrence of other infectious …

The Ebola virus (EBOV) epidemic in West Africa increased the focus on vaccine
development against this hemorrhagic fever–causing pathogen, and as a consequence …

The filoviruses Marburg virus and Ebola virus cause severe hemorrhagic fever with high
mortality in humans and nonhuman primates. Among the most promising filovirus vaccines …

Abstract Background The family Filoviridae consists of several virus members known to
cause significant mortality and disease in humans. Among these, Ebola virus (EBOV) …

The devastating Ebola virus (EBOV) epidemic in West Africa in 2013–2016 accelerated the
progress of several vaccines and antivirals through clinical trials, including the replication …